Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
104 hedge funds and large institutions have $139M invested in Kezar Life Sciences in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 44 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 33
21% more call options, than puts
Call options by funds: $1.78M | Put options by funds: $1.48M
6.3% less ownership
Funds ownership: 84.85% → 78.55% (-6.3%)
24% less funds holding
Funds holding: 136 → 104 (-32)
26% less capital invested
Capital invested by funds: $188M → $139M (-$48.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
73% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$3.78M |
| 2 |
Millennium Management
New York
|
+$3.13M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.02M |
| 4 |
BlackRock
New York
|
+$1.64M |
| 5 |
Two Sigma Advisers
New York
|
+$916K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$5.58M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$4.48M |
| 3 |
CA
CHI Advisors
New York
|
-$2.16M |
| 4 |
Barclays
London,
United Kingdom
|
-$2.12M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.46M |
KZR Hedge Fund Activity: Q2 2023 in Review
104 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2023, worth a combined $139M — down 26% from $188M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of KZR and 12 opened new positions — a net loss of 32 holders — while 33 trimmed existing stakes and 45 added.
The largest buyer was Prosight Management, adding an estimated $3.78M. The largest seller was State Street, cutting an estimated $5.58M.
- 104 institutional investors held Kezar Life Sciences (KZR) as of Q2 2023, down from 136 in Q1 2023.
- Funds reported $139M of Kezar Life Sciences stock for Q2 2023, down 26% quarter-over-quarter.
- 12 funds opened new Kezar Life Sciences positions in Q2 2023 and 44 closed out, a net change of -32 holders.
- The largest Kezar Life Sciences buyer in Q2 2023 was Prosight Management, an estimated $3.78M added.
- The largest Kezar Life Sciences seller in Q2 2023 was State Street, an estimated $5.58M sold.
Based on aggregated 13F filings for Q2 2023.